Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease

Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease

Abstract Objective To evaluate the cardiovascular and renal benefits of finerenone, sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagonlike peptide-1 receptor agonists (GLP-1 RA) in patients with Type 2 Diabetes Mellitus (T2DM) and chronic kidney disease (CKD) with network meta-analysis....

Full description

Bibliographic Details
Main Authors: Yaofu Zhang, Li Jiang, Junheng Wang, Tongxin Wang, Chieh Chien, Weijun Huang, Xiaozhe Fu, Yonghua Xiao, Qiang Fu, Shidong Wang, Jinxi Zhao
Format: Article
Language:English
Published: BMC 2022-11-01
Series:Cardiovascular Diabetology
Subjects:
Finerenone
SGLT2 inhibitors
GLP-1 receptor agonist
Network meta-analysis
Cardiovascular outcome
Renal outcome
Online Access:https://doi.org/10.1186/s12933-022-01676-5

Internet

https://doi.org/10.1186/s12933-022-01676-5

Similar Items